Saudi Journal of Gastroenterology
Home About us Instructions Submission Subscribe Advertise Contact Login    Print this page  Email this page Small font sizeDefault font sizeIncrease font size 
Users Online: 1422 


 
Table of Contents   
LETTER TO EDITOR  
Year : 2014  |  Volume : 20  |  Issue : 3  |  Page : 203-204
Serum paraoxonase and malondialdehyde levels in asymptomatic cholelithiasis


1 Department of Biochemistry, Agri Military Hospital, Agri, Turkey
2 Department of Biochemistry, Sirnak Military Hospital, Sirnak, Turkey
3 Department of Biochemistry, Sarikamis Military Hospital, Kars, Turkey

Click here for correspondence address and email

Date of Web Publication22-May-2014
 

How to cite this article:
Agilli M, Aydin FN, Aydin I. Serum paraoxonase and malondialdehyde levels in asymptomatic cholelithiasis. Saudi J Gastroenterol 2014;20:203-4

How to cite this URL:
Agilli M, Aydin FN, Aydin I. Serum paraoxonase and malondialdehyde levels in asymptomatic cholelithiasis. Saudi J Gastroenterol [serial online] 2014 [cited 2019 Nov 15];20:203-4. Available from: http://www.saudijgastro.com/text.asp?2014/20/3/203/133039


Sir,

We have read with great interest the published article by Atamer et al., entitled "Evaluation of Paraoxonase, Malondialdehyde, and Lipoprotein Levels in Patients with Asymptomatic Cholelithiasis". [1] Authors have found lower serum paraoxonase and higher serum malondialdehyde (MDA) levels in patients with asymptomatic cholelithiasis. However, we think that some more points should be discussed.

The authors measured C-reactive protein (CRP) to demonstrate inflammatory status in the body. If other tests showing inflammatory status as erythrocyte sedimentation rate and complete blood count were assigned in addition to CRP, determining the study groups could be more reliable. [2]

Moselhy et al., reported the inaccuracy for thiobarbituric acid reactive substances (TBARS) assays on quantifying MDA, and they stated that TBARS approach may limit the likelihood of detecting true differences in the level of lipid peroxidation in clinical studies. [3] The poor specificity of TBARS assays could lead to an overestimation of MDA levels in human plasma. [3] If a chromatographic assay that is accepted to have satisfactory analytic performance to determine MDA levels as a true indicator of lipid peroxidation in biological matrices was employed in this study, interpretation of the results would have been more reliable.

There is an inconsistency between [Table 1] and [Table 2] on aspartate aminotransaminase (AST) and gamma-glutamyl transferase (GGT) levels of cholelithiasis group. Both parameters are lower in glucose >100 mg/dL and glucose <100 mg/dL groups of cholelithiasis in [Table 2] than whole cholelithiasis group in [Table 1], which could not be possible. Although there were no significant differences on these parameters between the control and the cholelithiasis groups according to [Table 1], these data cause confusion and loss of reliability of the study. Also other tables should be revised because of similar errors.
Table 1: Comparison of clinical and biochemical parameters between healthy control and cholelithiasis group

Click here to view
Table 2: Comparison of age, body mass index and laboratory parameters between subjects with cholelithiasis who have fasting blood glucose >100 mg/dL and <100 mg/dL

Click here to view


The 2001 National Cholesterol Education Program Adult Treatment Panel III report about metabolic syndrome diagnostic criteria include abdominal obesity, hypertriglyceridemia, decreased high-density lipoprotein cholesterol, high blood pressure, and hyperglycemia. [4] As it is known, metabolic syndrome is a risk factor for cholelithiasis. [5] In this study, cholelithiasis group consists of individuals, majority of whom have one or more metabolic syndrome criteria. In this regard, it is questionable if the findings of this study rely on cholelithiasis or metabolic syndrome itself. Namely, it is the main point whether cholelithiasis is a cause for these results or a result of metabolic syndrome beside other findings. In this view, explanation of these concerns would certainly provide the readers clearer information.

 
   References Top

1.Atamer A, Kurdas-Ovunc AO, Yesil A, Atamer Y. Evaluation of paraoxonase, malondialdehyde, and lipoprotein levels in patients with asymptomatic cholelithiasis. Saudi J Gastroenterol 2014;20:66-73.  Back to cited text no. 1
[PUBMED]  Medknow Journal  
2.Kono T, Otsuka M, Ito M, Misawa M, Hoshioka A, Suzuki M, et al. Negative C-reactive protein in children with bacterial infection. Pediatr Int 1999;41:496-9.  Back to cited text no. 2
    
3.Moselhy HF, Reid RG, Yousef S, Boyle SP. A specific, accurate, and sensitive measure of total plasma malondialdehyde by HPLC. J Lipid Res 2013;54:852-8.  Back to cited text no. 3
    
4.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.  Back to cited text no. 4
[PUBMED]    
5.Ata N, Kucukazman M, Yavuz B, Bulus H, Dal K, Ertugrul DT, et al. The metabolic syndrome is associated with complicated gallstone disease. Can J Gastroenterol 2011;25:274-6.  Back to cited text no. 5
    

Top
Correspondence Address:
Mehmet Agilli
Department of Biochemistry, Agri Military Hospital, Agri
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1319-3767.133039

Rights and Permissions



 
 
    Tables

  [Table 1], [Table 2]



 

Top
  
 
  Search
 
  
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Email Alert *
    Add to My List *
* Registration required (free)  


    References
    Article Tables

 Article Access Statistics
    Viewed1067    
    Printed14    
    Emailed0    
    PDF Downloaded169    
    Comments [Add]    

Recommend this journal